Glaukos

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

FDA And CDC Involvement

News

Health Care

Movers

Trading Ideas

General

GKOS

Glaukos&#39; Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its non-invasive treatment potential.

FDA Sets Decision Date For Glaukos&#39; Keratoconus Treatment Without The Need Of Surgery

Wall-Street-ai7-1

Market Summary

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

Real Estate

$BTC

$ETH

CELH

FANG

GLOB

MELI

REAL

RIVN

SMMT

All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook. 

Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What&#39;s Driving Markets Friday?

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Analyst Color

Earnings

Guidance

Analyst Ratings

Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as the company expands its business model.

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

Glaukos Corp

Press Releases

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Glaukos Announces Third Quarter 2024 Financial Results

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Wells Fargo

Needham

Mizuho

Piper Sandler

Stifel

Comments

Glaukos

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga